-
Completion of Due Diligence and signing of Contract for Sale
December 23, 2004
Further to the Company's advise to the market on the 11 November 2004 we wish to advise that Due Diligence has been completed and a contract for sale has been signed with Vital Diagnostics Pty Limited.
-
Form 604 Notice of change of interests of substantial holder
December 23, 2004
-
Form 605 Notice of ceasing to be a substantial holder
December 16, 2004
-
Appendix 3Y - Change of Director's Interest Notice
December 13, 2004
-
Appendix 3B - New issue announcement, application for quotation of additional securities and agreement
December 02, 2004
-
Initial Director's Notice - Appendix 3X
December 01, 2004
-
Final Director's Interest Notice - Appendix 3Z
December 01, 2004
-
Results of the Annual General Meeting
November 30, 2004
The Company is pleased to announce that all resolutions put to shareholders at today's Annual General Meeting were passed on a show of hands. Proxy votes received were as follows:
-
Analytica Limited Chairmans Address to Members at the Annual General Meeting of Members in Brisbane on 30 November 2004
November 30, 2004
-
Analytica announces first retractable syringe prototype is now completed
November 29, 2004
Analytica is pleased to announce that it has produced the first working prototype of a 5 ml model retractable syringe. One thousand units of this model will now be produced for exhaustive testing of the retraction mechanism which is the unique and patented element in the design. Subsequent product development will be done concomitant with meeting specific regulatory compliance needs which will be dictated by Therapeutic Goods Administration. Obtaining TGA licence and product listing will require the maintenance of diligent development controls, manufacturing systems and quality testing and release procedures.
-
Change of underwriter payment obligations under the underwriting agreement of the June 2004 rights issue
November 12, 2004
The Company has today agreed to extend the terms of the payment obligation of the underwriter arising from the underwriting agreement of the Company's prospectus that closed in June 2004.
-
Managing Directors Employment Contract and Initial Directors Notice - Appendix 3X
November 12, 2004
As announced today Mr Stephen Goodall has been appointed Managing Director of the Company effective today.
-
Analytica signs heads of agreement to divest diagnostic business
November 12, 2004
The Board of Analytica advises ASX pursuant to Listing Rule 3.1 that the Company has signed a non-binding Heads of Agreement (HOA) to divest its diagnostic business. An Agreement has been signed with Vital Diagnostics Pty Limited (Vital) which if implemented will result in Vital acquiring the Company's diagnostic business on a ?walk in walk out? basis.
-
Changes to Board Structure
November 12, 2004
I report to the market pursuant to Listing Rule 3.1 concerning Continuous Disclosure as follows: The appointment of Mr Stephen Goodall as Managing Director and Director of Analytica Limited effective today 12 November 2004; The resignation of Mr van der Pluijm as both Managing Director and a Director of Analytica Limited effective 30 November 2004 and The appointment of two (2) new directors; Mr Jim Heckathorn and Mr David Gooch effective following the Annual General Meeting that is scheduled to be held on 30 November 2004. These changes reflect the company's strategy enforced by the Board of developing its medical technology business around its: Safety syringe and retractions technology and its recently acquired auto-burette business.
-
Appendix 4C and Review of Operations Quarter ending 30 September 2004
October 29, 2004
-
Analytica executes Exclusive Licence for Auto-burette Medical Device
October 27, 2004
Medical device company Analytica announced today that it has executed a worldwide exclusive licence agreement covering all patents, further development and commercialisation of a unique auto-burette medical device.
-
Notice Of Annual General Meeting
October 25, 2004
-
Notice Of Annual General Meeting - Appointment Of Proxy
October 25, 2004
-
2004 Annual Report
October 25, 2004
-
Form 604 - Notice of Change of Interests of Substantial Holder
October 18, 2004
-
Form 604 - Notice of Change of Interests of Substantial Holder
October 15, 2004
-
Appendix 3Y - Change of Director's Interest Notice
October 15, 2004
-
Board Changes: Analytica Ltd and Psiron Ltd
October 05, 2004
As of today, Ms Julie Nutting, CEO, Psiron Ltd, will step down from the Board of Directors of Analytica Ltd. This will allow her more time to focus on the new world-class cancer project successfully acquired by Psiron in August.
-
Analytica Appoints advisory board
September 17, 2004
Medical technology company Analytica Ltd announced that it has appointed an advisory board to provide independent expert advice on and future assistance with Analytica's ongoing business development and strategy. ?The appointment will further expand Analytica's expertise in the medical technology area?, said Ron van der Pluijm, Analytica's Chief Executive. ?Adding an advisory board of this quality brings further skills and experience to our overall operation and complements our existing management team?.
-
Appendix 3Y Change Of Director's Interest Notice
September 06, 2004
-
Financial Annual Report for the year ended 30 June 2004
August 31, 2004
-
Appendix 4E and Audited Annual Report for the 12 months ended 30 June 2004
August 31, 2004
TABLE OF CONTENTS
Corporate Information
Chairman's Letter
Directors' Report
Corporate Governance Statement
Directors' Declaration
Statement of Financial Performance
Statement of Financial Position
Statement of Cash Flows
Notes to the Financial Statements
Independent Audit Report
-
Notice of Initial Substantial Holder - Form 603
August 11, 2004
-
Release of shares from voluntary escrow
August 04, 2004
The Company advises that the voluntary escrow restrictions on the 20,000,000 shares issued to Australian Technology Innovation Fund Ltd as part of the recent acquisition price of the Retractable Syringe Technology which was to be in place to 28 December 2004, will be lifted effective 19 August 2004. The Australian Technology Innovation Fund Ltd has approached the Company and advised that it wishes to pay an in specie dividend to its shareholders by distributing its shareholding in Analytica Ltd to its shareholders.
-
Appendix 4E - Preliminary Final Report
July 12, 2004
-
Appendix 3X - Initial Director's Interest Notice
July 09, 2004
-
Form 604 - Notice of Change of Interests of Substantial Holder
July 06, 2004
-
Form 603 - Notice of Initial Substantial Holder
July 05, 2004
-
Appendix 3Y Change of Director's Interest Notice
July 02, 2004
-
Analytica appoints Dr Michael Monsour as Director
July 01, 2004
Medical technology company Analytica Limited has announced the appointment of Dr Michael Monsour as non-executive director. Dr Monsour is a medical practitioner with business interests in Queensland medical centres. He operates a medical management company that provides management support to medical practitioners and is also one of Australia's leading providers of software systems for Occupational Health and Safety and Medical Accounting.
-
2004 Annual Report
June 30, 2004
-
Analytica allots shares and takes full control of Brewer Retractable Technologies Pty Ltd
June 28, 2004
Medical technology company Analytica Ltd has today allotted the shares and options for its recently concluded $4.2 million underwritten rights issue. Significantly, the allotment of shares was the last precondition for Analytica's acquisition of Brewer Retractable Technologies Pty Ltd (?BRT?). Analytica has now taken full ownership of BRT, which ensures the company is now well-positioned to accelerate the commercialisation of BRT's unique vacuum-activated retractable syringe.
-
Further accolades for Analytica syringe
June 22, 2004
The non-reusable safety syringe being developed by medical technology company Analytica Ltd, has received further recognition at the 2004 Queensland Design Awards. It has been awarded the inaugural People's Choice Award by visitors to the Queensland Art Gallery. Analytica's Non-reusable Automatically Retracting Safety Syringe also recently won the Industrial Design Category of the 2004 Queensland Design Awards. It also received an Award of Merit, which is only awarded to those projects that demonstrate the highest level of achievement within its category in accordance with the judging criteria. Work by finalists and winners of the 2004 Queensland Design Awards were on display at the Queensland Art Gallery in an exhibition titled ?Design Excellence in Queensland?.
-
Successful Conclusion of Rights Issue
June 17, 2004
Medical technology company, Analytica Limited, today announced that its $4.2 million rights issue was strongly supported with 28,892,095 shares (58.1%) of share entitlements being taken up by shareholders. The shortfall is currently being allocated by the underwriter and sub-underwriters, while new shares will be allotted to shareholders on 22 June 2004. Managing Director Ron van der Pluijm, said that the raising of these funds would enable Analytica to aggressively move forward with the development and commercialisation of its recently acquired retractable syringe technology. More than one third of the funds raised will be used to bed down this unique technology to enable the start of commercialisation of the syringe across what is a significant potential market.
-
Analytica syringe wins 2004 Queensland Design Award
June 07, 2004
Analytica's vacuum retractable syringe has won the Industrial Design Category of the 2004 Queensland Design Awards. In addition it has also won an Award of Merit, which is only awarded to those projects that demonstrate the highest level of achievement within its category in accordance with the judging criteria. As the Queensland Design Awards does not have a separate healthcare category, Analytica's design was entered into the wider category of Industrial Designs. "It is further recognition for the simple yet advanced design of Analytica's vacuum retractable syringe" said Ron van der Pluijm, Analytica's Managing Director.
-
Shareholder Presentations - Analytica Ltd
June 02, 2004
Analytica is holding information briefings for shareholders at various locations throughout Australia over the next two weeks. Conducting the briefings will be Managing Director, Mr Ron Van Der Pluijm who will be accompanied by Mr Ivan Brewer, R&D Consultant Retractable Technologies. He will deliver an operational and strategic update, with a particular focus on the Company's recent acquisition of the Brewer retractable technologies. Another key issue on the agenda is Analytica's current non-renounceable rights issue to raise approximately $4.2 million.
-
Letter to Shareholders Re: Rights Issue
May 14, 2004
On 13 May 2004 Analytica lodged its prospectus for the underwritten non-renouceable rights issue to raise approximately $4.2 million with ASIC and the ASX. A copy of the prospectus is available on the ASX website (www.asx.com.au) as well as on the Company's website (www.analyticaltd.com). The funds are raised to develop and commercialise Analytica's recently acquired retractable technologies and, additionally, to help to retire the Company's debt. Psiron Ltd, Analytica's major shareholder, has agreed to participate in the capital raising and will contribute $1.6 million as a debt for equity swap. As a result Analytica will not only be debt free, but will also be well positioned to develop its existing technologies and pursue further merger and acquisition opportunities.
-
Analytica Ltd Non-renounceable Rights Issue
May 13, 2004
The Board of Directors of Analytica Ltd is pleased to offer you the opportunity to participate in a $4.2 million capital raising. The funds raised will be used to develop and commercialise Analytica's recently acquired retractable technologies and, additionally, will also help retire the Company's debt. In this respect, Analytica's major shareholder, Psiron Ltd, has agreed to participate in the capital raising and will contribute $1.6 million as a debt for equity swap. As a result Analytica will not only be debt free, but will also be well positioned to develop its existing technologies and pursue further merger and acquisition opportunities.
-
Fully underwritten rights issue raising $4.2 million
May 07, 2004
Medical Technology company Analytica Limited announced today that it is raising approximately $4.2 million through a fully underwritten non-renounceable rights issue.
-
Appendix 4C and Review of Operations - Quarter Ending 31 March 2004
April 30, 2004
The highlight of the March financial quarter was Analytica's execution of an agreement to acquire Brewer Retractable Technologies Pty Ltd (Brewer). Brewer owns patents, patent applications and know-how for a vacuum-activated retractable syringe. The Brewer intellectual property can also be adapted to other medical technologies, including blood collection devices and cannulas. The acquisition of Brewer was unanimously approved at a meeting of Analytica shareholders on 31 March. Since completing the acquisition, Analytica has forged ahead with development of the Brewer technology. The actual steel tooling required to produce the commercial prototype syringe has been manufactured and is currently being optimised. The development timeline remains on track, with actual testing of the syringe expected to commence in the middle of this year. During this quarter Analytica also spent a significant amount of time presenting its overall growth strategy and details of its Brewer acquisition to the financial community. Presentations were made in most major cities and were very well-received.
-
Results of shareholders' meeting
March 31, 2004
In accordance with the Listing Rule 3.13.2 we advise that at the General Meeting of Shareholders of Analytica Ltd held earlier today, items 1 to 6 as set out below, were unanimously approved on a vote by a show of hands.
-
Brewer Presentation
March 31, 2004
Presentation made at the General Meeting of Shareholders on 31 March 2004
-
Notice of General Meeting
March 01, 2004
Notice is given that a general meeting of Analytica Ltd (?Company?) will be held in the Essex Room at Quay West Suites, 98 Gloucester Street, The Rocks, Sydney, NSW 2000, Australia on 31 March 2004 at 10.30am.
-
Appendix 4D Six months ended ('current period') 31 December 2003
February 27, 2004
-
Analytica Letter to Shareholders
February 20, 2004
-
Analytica Overview Presentation to Brokers
February 19, 2004
-
Analytica varies terms of proposed Brewer acquisition New agreement more favourable to shareholders
February 03, 2004
Analytica Limited (ASX:ALT) today announced that it had improved the terms of its previously announced agreement to acquire Brewer Retractable Technologies Pty Ltd ("Brewer"). The commercial terms of the agreement - which have been updated following subsequent discussions between Analytica and Brewer - are now more closely linked to market acceptance and commercial success of the Brewer technology.
-
Appendix 4C and Review of Operations Quarter ending 31 December 2003
January 29, 2004
Analytica is a medical technology company that is focused on trading businesses and late stage development projects in the life sciences industry. Its strategy is to grow through mergers and acquisitions, as well as internal product development.
-
Change in substantial notice by PSX in ALT released to the market
January 20, 2004
Form 604 Notice of change of interests of substantial holder
-
Analytica allots shares under Share Purchase Plan
January 16, 2004
Medical technology company, Analytica Limited (ASX: ALT) today granted shares to participating shareholders under the terms of its Share Purchase Plan (SPP). The funds raised in the SPP will be used by Analytica to finalise its proposed acquisition of Brewer Retractable Technologies; provide capital to develop the Brewer syringe prototypes and prototype tooling for the Brewer technology; and for working capital. The SPP was structured to benefit Analytica's loyal shareholders, with an issue price at 20 per cent discount to the volume weighted average trading price over the five days leading up to 24 December 2003, with a minimum of 8 cents. The shares have been issued at 8.2 cents, and raised $707,520 (net of the underwriting fee) for the Company. Attached is appendix 3B.
